Display options
Cite
Png G, Barysenka A, Repetto L, et al. Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat Commun. 2021;12(1):7042doi: 10.1038/s41467-021-27387-1.
Png, G., Barysenka, A., Repetto, L., Navarro, P., Shen, X., Pietzner, M., Wheeler, E., Wareham, N. J., Langenberg, C., Tsafantakis, E., Karaleftheri, M., Dedoussis, G., Mälarstig, A., Wilson, J. F., Gilly, A., & Zeggini, E. (2021). Mapping the serum proteome to neurological diseases using whole genome sequencing. Nature communications, 12(1), 7042. https://doi.org/10.1038/s41467-021-27387-1
Png, Grace, et al. "Mapping the serum proteome to neurological diseases using whole genome sequencing." Nature communications vol. 12,1 (2021): 7042. doi: https://doi.org/10.1038/s41467-021-27387-1
Png G, Barysenka A, Repetto L, Navarro P, Shen X, Pietzner M, Wheeler E, Wareham NJ, Langenberg C, Tsafantakis E, Karaleftheri M, Dedoussis G, Mälarstig A, Wilson JF, Gilly A, Zeggini E. Mapping the serum proteome to neurological diseases using whole genome sequencing. Nat Commun. 2021 Dec 02;12(1):7042. doi: 10.1038/s41467-021-27387-1. PMID: 34857772.
Copy Download .nbib Format: NLM
Share it on

Nat Commun. 2021 Dec 02;12(1):7042. doi: 10.1038/s41467-021-27387-1.

Mapping the serum proteome to neurological diseases using whole genome sequencing.

Nature communications

Grace Png, Andrei Barysenka, Linda Repetto, Pau Navarro, Xia Shen, Maik Pietzner, Eleanor Wheeler, Nicholas J Wareham, Claudia Langenberg, Emmanouil Tsafantakis, Maria Karaleftheri, George Dedoussis, Anders Mälarstig, James F Wilson, Arthur Gilly, Eleftheria Zeggini

Affiliations

  1. Institute of Translational Genomics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. [email protected].
  2. TUM School of Medicine, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany. [email protected].
  3. Institute of Translational Genomics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany.
  4. Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK.
  5. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  6. Greater Bay Area Institute of Precision Medicine (Guangzhou), Fudan University, Guangzhou, China.
  7. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
  8. MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
  9. Computational Medicine, Berlin Institute of Health (BIH), Charité University Medicine, Berlin, Germany.
  10. Anogia Medical Centre, Anogia, Greece.
  11. Echinos Medical Centre, Echinos, Greece.
  12. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, Athens, Greece.
  13. Department of Medicine, Karolinska Institute, Solna, Sweden.
  14. Emerging Science & Innovation, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.
  15. Institute of Translational Genomics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany. [email protected].
  16. TUM School of Medicine, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany. [email protected].

PMID: 34857772 DOI: 10.1038/s41467-021-27387-1

Abstract

Despite the increasing global burden of neurological disorders, there is a lack of effective diagnostic and therapeutic biomarkers. Proteins are often dysregulated in disease and have a strong genetic component. Here, we carry out a protein quantitative trait locus analysis of 184 neurologically-relevant proteins, using whole genome sequencing data from two isolated population-based cohorts (N = 2893). In doing so, we elucidate the genetic landscape of the circulating proteome and its connection to neurological disorders. We detect 214 independently-associated variants for 107 proteins, the majority of which (76%) are cis-acting, including 114 variants that have not been previously identified. Using two-sample Mendelian randomisation, we identify causal associations between serum CD33 and Alzheimer's disease, GPNMB and Parkinson's disease, and MSR1 and schizophrenia, describing their clinical potential and highlighting drug repurposing opportunities.

© 2021. The Author(s).

References

  1. Feigin, V. L. et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 459–480 (2019). - PubMed
  2. GBD. 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16, 877–897 (2017). - PubMed
  3. Cross-Disorder Group of the Psychiatric Genomics Consortium. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell. 179, 7 (2019). - PubMed
  4. De Jager, P. L., Yang, H.-S. & Bennett, D. A. Deconstructing and targeting the genomic architecture of human neurodegeneration. Nat. Neurosci. 21, 1310–1317 (2018). - PubMed
  5. Ayano, G. et al. Misdiagnosis, detection rate, and associated factors of severe psychiatric disorders in specialized psychiatry centers in Ethiopia. Ann. Gen. Psychiatry 20, 10 (2021). - PubMed
  6. Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021). - PubMed
  7. Hillary, R. F. et al. Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. Nat. Commun. 10, 3160 (2019). - PubMed
  8. Wingo, A. P. et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis. Nat. Genet. https://doi.org/10.1038/s41588-020-00773-z (2021). - PubMed
  9. Folkersen, L. et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab 2, 1135–1148 (2020). - PubMed
  10. Yao, C. et al. Genome‐wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018). - PubMed
  11. Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018). - PubMed
  12. Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat. Commun. 8, 14357 (2017). - PubMed
  13. Alkebsi, L. et al. Validation of the accuracy of self-reported ABO blood types in the Japan Nurses’ Health Study. Asian Pac. J. Cancer Prev. 20, 789–793 (2019). - PubMed
  14. Sasayama, D. et al. Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Hum. Mol. Genet. https://doi.org/10.1093/hmg/ddw366 (2016). - PubMed
  15. Parham, P. MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201–214 (2005). - PubMed
  16. Jenkins, R. W., Canals, D. & Hannun, Y. A. Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell. Signal. 21, 836–846 (2009). - PubMed
  17. Park, M. H., Jin, H. K. & Bae, J.-S. Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase. Exp. Mol. Med. 52, 380–389 (2020). - PubMed
  18. Lee, J. K. et al. Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer’s disease. J. Exp. Med. 211, 1551–1570 (2014). - PubMed
  19. Cutler, R. G., Pedersen, W. A., Camandola, S., Rothstein, J. D. & Mattson, M. P. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 52, 448–457 (2002). - PubMed
  20. Yang, J. et al. Genetic variance estimation with imputed variants finds negligible missing heritability for human height and body mass index. Nat. Genet. 47, 1114–1120 (2015). - PubMed
  21. Evans, L. M. et al. Comparison of methods that use whole genome data to estimate the heritability and genetic architecture of complex traits. Nat. Genet. 50, 737–745 (2018). - PubMed
  22. Li, J. et al. Proportion of neuropathic pain in the back region in chronic low back pain patients -a multicenter investigation. Sci. Rep. 8, 16537 (2018). - PubMed
  23. Thakur, M., Dickenson, A. H. & Baron, R. Osteoarthritis pain: nociceptive or neuropathic? Nat. Rev. Rheumatol. 10, 374–380 (2014). - PubMed
  24. Pisanu, C. et al. High leptin levels are associated with migraine with aura. Cephalalgia Int. J. Headache 37, 435–441 (2017). - PubMed
  25. Zhao, T. et al. Common variants in LTBP3 gene contributed to the risk of hip osteoarthritis in Han Chinese population. Biosci. Rep. 40, BSR20192999 (2020). - PubMed
  26. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 43, 977–983 (2011). - PubMed
  27. Gilabert-Juan, J. et al. Semaphorin and plexin gene expression is altered in the prefrontal cortex of schizophrenia patients with and without auditory hallucinations. Psychiatry Res. 229, 850–857 (2015). - PubMed
  28. Tavares, H., Yacubian, J., Talib, L. L., Barbosa, N. R. & Gattaz, W. F. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 61, 1–6 (2003). - PubMed
  29. Szláma, G., Kondás, K., Trexler, M. & Patthy, L. WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity. FEBS J. 277, 5040–5050 (2010). - PubMed
  30. Taylor-Gjevre, R. M., Nair, B. V. & Gjevre, J. A. Obstructive sleep apnoea in relation to rheumatic disease. Rheumatol. Oxf. Engl. 52, 15–21 (2013). - PubMed
  31. Kang, J.-H. & Lin, H.-C. Obstructive sleep apnea and the risk of autoimmune diseases: a longitudinal population-based study. Sleep. Med. 13, 583–588 (2012). - PubMed
  32. Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat. Genet. 46, 989–993 (2014). - PubMed
  33. Moloney, E. B., Moskites, A., Ferrari, E. J., Isacson, O. & Hallett, P. J. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol. Dis. 120, 1–11 (2018). - PubMed
  34. Rose, A. A. N. et al. ADAM10 releases a soluble form of the GPNMB/osteoactivin extracellular domain with angiogenic properties. PLoS ONE 5, e12093 (2010). - PubMed
  35. Lambert, J. C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 45, 1452–1458 (2013). - PubMed
  36. Griciuc, A. et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631–643 (2013). - PubMed
  37. Bradshaw, E. M. et al. CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848–850 (2013). - PubMed
  38. Goes, F. S. et al. Genome-wide association study of schizophrenia in Ashkenazi Jews. Am. J. Med. Genet. B Neuropsychiatr. Genet. 168, 649–659 (2015). - PubMed
  39. Sherva, R. et al. Genome-wide association study of rate of cognitive decline in Alzheimer’s disease patients identifies novel genes and pathways. Alzheimers Dement. J. Alzheimers Assoc. 16, 1134–1145 (2020). - PubMed
  40. Frenkel, D. et al. Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer’s-like disease progression. Nat. Commun. 4, 2030 (2013). - PubMed
  41. Shichita, T. et al. MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. Nat. Med. 23, 723–732 (2017). - PubMed
  42. Kunjathoor, V. V. et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277, 49982–49988 (2002). - PubMed
  43. Kelley, J. L., Ozment, T. R., Li, C., Schweitzer, J. B. & Williams, D. L. Scavenger receptor-A (CD204): a two-edged sword in health and disease. Crit. Rev. Immunol. 34, 241–261 (2014). - PubMed
  44. Cornejo, F. et al. Scavenger Receptor-A deficiency impairs immune response of microglia and astrocytes potentiating Alzheimer’s disease pathophysiology. Brain Behav. Immun. 69, 336–350 (2018). - PubMed
  45. McCollum, L. A. & Roberts, R. C. Uncovering the role of the nucleus accumbens in schizophrenia: a postmortem analysis of tyrosine hydroxylase and vesicular glutamate transporters. Schizophr. Res. 169, 369–373 (2015). - PubMed
  46. McCollum, L. A., Walker, C. K., Roche, J. K. & Roberts, R. C. Elevated excitatory input to the nucleus accumbens in schizophrenia: a postmortem ultrastructural study. Schizophr. Bull. 41, 1123–1132 (2015). - PubMed
  47. Chaudhury, D. et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature 493, 532–536 (2013). - PubMed
  48. Dujardin, K. & Sgambato, V. Neuropsychiatric disorders in Parkinson’s Disease: what do we know about the role of dopaminergic and non-dopaminergic systems? Front. Neurosci. 14, 25 (2020). - PubMed
  49. Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.World Psychiatry Off. J. World Psychiatr. Assoc. 16, 163–180 (2017). - PubMed
  50. Davis, C. A. et al. The Encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids Res. 46, D794–D801 (2018). - PubMed
  51. Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19–34 (2017). - PubMed
  52. Okuno, Y., Matsumura, N. & Oguro, S. Transcatheter arterial embolization using imipenem/cilastatin sodium for tendinopathy and enthesopathy refractory to nonsurgical management. J. Vasc. Interv. Radiol. 24, 787–792 (2013). - PubMed
  53. Lee, S. H. et al. Clinical outcomes of transcatheter arterial embolisation for chronic knee pain: mild-to-moderate versus severe knee osteoarthritis. Cardiovasc. Interv. Radiol. 42, 1530–1536 (2019). - PubMed
  54. Malik, M. et al. Genetics of CD33 in Alzheimer’s disease and acute myeloid leukemia. Hum. Mol. Genet. 24, 3557–3570 (2015). - PubMed
  55. Hiligsmann, M. et al. Health economics in the field of osteoarthritis: an expert’s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin. Arthritis Rheum. 43, 303–313 (2013). - PubMed
  56. Tachmazidou, I. et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat. Genet. 51, 230–236 (2019). - PubMed
  57. Miller, R. E., Lu, Y., Tortorella, M. D. & Malfait, A.-M. Genetically engineered mouse models reveal the importance of proteases as osteoarthritis drug targets. Curr. Rheumatol. Rep. 15, 350 (2013). - PubMed
  58. Suhre, K., McCarthy, M. I. & Schwenk, J. M. Genetics meets proteomics: perspectives for large population-based studies. Nat. Rev. Genet. 22, 19–37 (2021). - PubMed
  59. Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5, e15004 (2010). - PubMed
  60. Pietzner, M. et al. Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nat. Commun. 11, 6397 (2020). - PubMed
  61. Pietzner, M. et al. Cross-platform proteomics to advance genetic prioritisation strategies. http://biorxiv.org/lookup/doi/10.1101/2021.03.18.435919 (2021). - PubMed
  62. Farmaki, A.-E. et al. The mountainous Cretan dietary patterns and their relationship with cardiovascular risk factors: the Hellenic Isolated Cohorts MANOLIS study. Public Health Nutr. 20, 1063–1074 (2017). - PubMed
  63. Gilly, A. et al. Very low-depth sequencing in a founder population identifies a cardioprotective APOC3 signal missed by genome-wide imputation. Hum. Mol. Genet. 25, 2360–2365 (2016). - PubMed
  64. Panoutsopoulou, K. et al. Genetic characterization of Greek population isolates reveals strong genetic drift at missense and trait-associated variants. Nat. Commun. 5, 5345 (2014). - PubMed
  65. Zhou, X. & Stephens, M. Genome-wide efficient mixed-model analysis for association studies. Nat. Genet. 44, 821–824 (2012). - PubMed
  66. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010). - PubMed
  67. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011). - PubMed
  68. Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4, 7 (2015). - PubMed
  69. Moskvina, V. & Schmidt, K. M. On multiple-testing correction in genome-wide association studies. Genet. Epidemiol. 32, 567–573 (2008). - PubMed
  70. Cheverud, J. M. A simple correction for multiple comparisons in interval mapping genome scans. Heredity 87, 52–58 (2001). - PubMed
  71. Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018). - PubMed
  72. McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016). - PubMed
  73. Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014). - PubMed
  74. Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics 32, 3207–3209 (2016). - PubMed
  75. Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 4851–4853 (2019). - PubMed
  76. Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 13, e1007081 (2017). - PubMed
  77. Hemani, G. et al. The MR-base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018). - PubMed
  78. Ochoa, D. et al. Open targets platform: supporting systematic drug–target identification and prioritisation. Nucleic Acids Res. 49, D1302–D1310 (2021). - PubMed
  79. Wishart, D. S. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668–D672 (2006). - PubMed

Publication Types